[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. National Toxicology Program: Toxicology and carcinogenesis studies of goldenseal root powder (Hydrastis Canadensis) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser; 2010 Aug;(562):1-188
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goldenseal root powder is used in folk medicine for the treatment of gastrointestinal disturbances, urinary disorders, hemorrhage, skin, mouth, and eye infections, and inflammation.
  • The incidences of hepatocellular adenoma were significantly increased in males and females exposed to 25,000 ppm, and the incidence of hepatocellular adenoma or carcinoma (combined) was significantly increased in 25,000 ppm males.
  • The incidences of hepatocellular adenoma occurred with a positive trend in males, and the incidences of multiple hepatocellular adenoma were significantly increased in 9,000 and 25,000 ppm males.
  • CONCLUSIONS: Under the conditions of these 2-year feed studies, there was clear evidence of carcinogenic activity of goldenseal root powder in male F344/N rats based on the increased incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined).
  • There was clear evidence of carcinogenic activity of goldenseal root powder in female F344/N rats based on the increased incidence of hepatocellular adenoma.
  • There was some evidence of carcinogenic activity of goldenseal root powder in male B6C3F1 mice based on the increased incidences of hepatoblastoma and multiple hepatocellular adenoma.
  • [MeSH-minor] Animals. Carcinogenicity Tests. Dose-Response Relationship, Drug. Female. Humans. Male. Mice. Mice, Inbred Strains. Powders. Rats. Rats, Inbred F344

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21372858.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Powders
  •  go-up   go-down


2. National Toxicology Program: Toxicology and carcinogenesis studies of sodium dichromate dihydrate (Cas No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies). Natl Toxicol Program Tech Rep Ser; 2008 Jul;(546):1-192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to sodium dichromate dihydrate resulted in the development of neoplasms of the squamous epithelium that lines the oral mucosa and tongue.
  • The incidences of squamous cell carcinoma in the oral mucosa of 516 mg/L male and female rats were significantly greater than those in the controls.
  • The incidences of squamous cell papilloma or squamous cell carcinoma (combined) of the oral mucosa or tongue of 516 mg/L male and female rats were significantly greater than those in the controls.
  • Exposure concentration-related nonneoplastic liver lesions were observed in males and females exposed to 57.3 mg/L or greater.
  • Increased incidences of histiocytic cellular infiltration also occurred in the small intestine (duodenum), mesenteric lymph node, and pancreatic lymph node of males and/or females exposed to 57.3 mg/L or greater.
  • The incidences of adenoma of the duodenum in 257.4 mg/L males and 172 and 516 mg/L females were significantly greater than those in the controls.
  • The incidence of adenoma of the jejunum in 516 mg/L females was significantly increased compared to that in the controls.
  • When the incidences of adenoma and carcinoma were combined for all sites of the small intestine, the incidences were significantly increased in 85.7 and 257.4 mg/L males and 172 and 516 mg/L females compared to those in the controls.
  • CONCLUSIONS: Under the conditions of these 2-year drinking water studies, there was clear evidence of carcinogenic activity of sodium dichromate dihydrate in male and female F344/N rats based on increased incidences of squamous cell neoplasms of the oral cavity.
  • [MeSH-minor] Administration, Oral. Animals. Female. Intestinal Neoplasms / chemically induced. Intestinal Neoplasms / pathology. Intestine, Small / drug effects. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Lymph Nodes / drug effects. Lymph Nodes / pathology. Male. Mice. Mice, Inbred Strains. Mouth Neoplasms / chemically induced. Mouth Neoplasms / pathology. Rats. Rats, Inbred F344. Water Supply

  • Hazardous Substances Data Bank. SODIUM DICHROMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716633.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromates; 0 / Water Pollutants, Chemical; C9G6VY6ZZ4 / sodium bichromate
  •  go-up   go-down


3. Ferrer Ramírez MJ, Silvestre Donat FJ, Estelles Ferriol E, Grau García Moreno D, López Martínez R: Recurrent infection of a complex odontoma following eruption in the mouth. Med Oral; 2001 Aug-Oct;6(4):269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent infection of a complex odontoma following eruption in the mouth.
  • A complex odontoma is described in a 22-year-old woman referring discomfort due to overinfection following its aperture into the oral cavity in the distal alveolar region of 2.6.
  • Initial treatment consisted of antibiotics and antiinflammatory drugs.
  • The surgical piece contained the amorphous adenoma mass and the tooth 2.7.

  • Genetic Alliance. consumer health - Odontoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11500642.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol; 2008 Apr;61(4):661-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase II trial to evaluate the efficacy of the anti-antiangiogenic agent thalidomide in metastatic neuroendocrine tumors.
  • Patients were started on oral thalidomide at a daily dose of 200 mg that was escalated to the target dose of 400 mg daily after 2 weeks.
  • Frequent Grade 1-2 toxicities were: fatigue (n = 13), constipation (n = 13), dry mouth (n = 12), somnolence (n = 12), dizziness/syncope (n = 10), weight gain (n = 5), and peripheral neuropathy (n = 5).
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Angiogenesis Inhibitors / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / secondary. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / secondary. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589846.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones; 106477-83-2 / pancreastatin; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


5. Franklin ME Jr, Díaz-E JA, Abrego D, Parra-Dávila E, Glass JL: Laparoscopic-assisted colonoscopic polypectomy: the Texas Endosurgery Institute experience. Dis Colon Rectum; 2000 Sep;43(9):1246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The advent of laparoscopic surgery has altered the manner by which surgical specialties address pathologies of the abdominal cavity.
  • The most common histopathologic diagnosis was tubulovillous adenoma in 28 polyps followed by villous adenoma in 11 polyps.
  • Pain at the trocar sites was managed with acetaminophen 600 mg by mouth as needed.
  • [MeSH-minor] Acetaminophen / therapeutic use. Adenoma, Villous / surgery. Aged. Analgesics, Non-Narcotic / therapeutic use. Colonic Neoplasms / surgery. Female. Humans. Male. Pain, Postoperative / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005491.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


6. Walker NJ, Crockett PW, Nyska A, Brix AE, Jokinen MP, Sells DM, Hailey JR, Easterling M, Haseman JK, Yin M, Wyde ME, Bucher JR, Portier CJ: Dose-additive carcinogenicity of a defined mixture of "dioxin-like compounds". Environ Health Perspect; 2005 Jan;113(1):43-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statistically based dose-response modeling indicated that the shape of the dose-response curves for hepatic, lung, and oral mucosal neoplasms was the same in studies of the three individual chemicals and the mixture.
  • Finally, we showed that use of the current World Health Organization dioxin TEF values adequately predicted the increased incidence of liver tumors (hepatocellular adenoma and cholangiocarcinoma) induced by exposure to the mixture.
  • [MeSH-major] Carcinogens / adverse effects. Dioxins / poisoning. Liver Neoplasms / chemically induced. Lung Neoplasms / chemically induced. Mouth Neoplasms / chemically induced
  • [MeSH-minor] Animals. Biological Assay. Dose-Response Relationship, Drug. Environmental Pollutants / administration & dosage. Environmental Pollutants / poisoning. Female. Humans. Rats. Rats, Sprague-Dawley. Reference Values. Risk Assessment. Tetrachlorodibenzodioxin / administration & dosage. Tetrachlorodibenzodioxin / poisoning

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Apr 17;422(6933):681-7 [12700752.001]
  • [Cites] Toxicol Sci. 2003 Jul;74(1):182-91 [12730615.001]
  • [Cites] Science. 2004 Jan 9;303(5655):226-9 [14716013.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Jan 15;194(2):156-68 [14736496.001]
  • [Cites] Toxicol Appl Pharmacol. 1978 Nov;46(2):279-303 [734660.001]
  • [Cites] Biometrics. 1988 Jun;44(2):417-31 [3390507.001]
  • [Cites] Environ Health Perspect. 1998 Dec;106(12):775-92 [9831538.001]
  • [Cites] Pharmacol Toxicol. 1991 Dec;69(6):450-8 [1766921.001]
  • [Cites] Eur J Pharmacol. 1992 Dec 1;228(4):179-99 [1335882.001]
  • [Cites] Toxicology. 1995 Dec 28;105(2-3):391-401 [8571375.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:55-89 [8970722.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Dec;147(2):267-80 [9439722.001]
  • [Cites] Crit Rev Toxicol. 1990;21(1):51-88 [2124811.001]
  • (PMID = 15626646.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Dioxins; 0 / Environmental Pollutants; DO80M48B6O / Tetrachlorodibenzodioxin
  • [Other-IDs] NLM/ PMC1253708
  •  go-up   go-down


7. Ito R, Nakayama H, Yoshida K, Oda N, Yasui W: Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol Rep; 2004 Nov;12(5):985-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the expression of maspin was examined in gastric mucosa, adenoma and carcinoma by immunohistochemistry and RT-PCR.
  • Maspin mRNA expression was lost in all of 8 gastric carcinoma cell lines that was retrieved after treatment with demethylation agent 5-aza-2'-deoxycytidine in 5 of 8 cell lines.
  • Loss of maspin expression may serve as a biological marker of high-grade malignancy.
  • [MeSH-major] Adenoma / metabolism. Azacitidine / analogs & derivatives. Gastric Mucosa / metabolism. Gene Expression Regulation, Neoplastic. Mouth Neoplasms / metabolism. Proteins / genetics. Serpins / genetics. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492782.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger; 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


8. Awazawa R, Yamamoto Y, Gushi M, Taira K, Yagi N, Asato Y, Hagiwara K, Uezato H: Case of pemphigus foliaceus that shifted into pemphigus vulgaris after adrenal tumor resection. J Dermatol; 2007 Aug;34(8):549-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological diagnosis of the removed tumor was a functional adrenal adenoma.
  • Additional p.o. medications of minocycline hydrochloride and nicotinic acid amides improved the symptoms to some extent.
  • However, oral cavity erosions appeared in December 2004, and the titer of anti-Dsg3 autoantibodies in serum elevated, suggesting a transition from PF to pemphigus vulgaris (PV). p.o. administration of corticosteroids started, which improved the symptoms significantly.
  • [MeSH-major] Adenoma / complications. Adrenal Gland Neoplasms / complications. Mouth Mucosa / pathology. Pemphigus / complications. Skin / pathology


9. Jeong HK, Park CH, Jun CH, Lee GH, Kim HI, Kim HS, Choi SK, Rew JS: A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection. J Korean Med Sci; 2007 Dec;22(6):1055-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective trial, patients undergoing ESD due to gastric adenoma or adenocarcinoma were randomly assigned to pantoprazole or famotidine.
  • Both drugs were given intravenously for the first 2 days, thereafter by mouth.
  • [MeSH-major] 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use. Anti-Ulcer Agents / therapeutic use. Famotidine / therapeutic use. Gastric Mucosa / surgery. Gastrointestinal Hemorrhage / prevention & control. Gastroscopy. Postoperative Hemorrhage / prevention & control. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Aug 3;343(5):310-6 [10922420.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):877-83 [17140890.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):576-81 [11923778.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):507-12 [12297765.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):567-79 [12665775.001]
  • [Cites] Gastrointest Endosc. 2003 May;57(6):687-90 [12709698.001]
  • [Cites] Endoscopy. 2003 Jul;35(7):611-2 [12822098.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):690-4 [12929067.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2635-41 [14687809.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):788-801 [15326574.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):808-10 [15326576.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):38-43 [21830.001]
  • [Cites] Scand J Gastroenterol Suppl. 1987;134:55-60 [2889260.001]
  • [Cites] Arch Intern Med. 1998 Jan 12;158(1):54-8 [9437379.001]
  • [Cites] Endoscopy. 1999 Jan;31(1):47-55 [10082409.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):251-6 [10425422.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Aug;13 Suppl 3:18-26 [10491725.001]
  • [Cites] Intern Med. 2004 Dec;43(12):1120-5 [15645644.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:111-5 [15943857.001]
  • [Cites] Dig Dis Sci. 2006 Jan;51(1):123-31 [16416224.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):243-9 [16427929.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7335-9 [16437638.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 1;24(5):837-43 [16918888.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):221-6 [11293753.001]
  • (PMID = 18162722.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Ulcer Agents; 5QZO15J2Z8 / Famotidine; D8TST4O562 / pantoprazole
  • [Other-IDs] NLM/ PMC2694634
  •  go-up   go-down






Advertisement